Home
About Us
Cancer Supportive Care
Pipeline
Business Development
News & Events
Contact
Company Overview
Strategy
Management
Board of Directors
Clinical Advisers
Investors
Overview
Post-Operative Nausea & Vomiting
Chemotherapy Induced Nausea & Vomiting
Xerostomia
Cancer Cachexia
Useful Links
Overview
APD421
APD403
APD515
APD209
News
Events
Downloads
Cancer Supportive Care
Enabling better cancer treatment, ensuring better quality of life.
News
4th January 2012
Acacia Pharma Initiates Phase II Study With APD421 In Post-Operative Nausea & Vomiting (PONV)
6th December 2011
Acacia Pharma Announces Positive Results From Phase IIa Cancer Cachexia Study
25th July 2011
Acacia Pharma Starts Phase II Clinical Trial With APD515 For Xerostomia
31st March 2011
Acacia Pharma Closes $10 Million Investment Round
16th February 2011
Acacia Pharma Initiates Phase IIa Clinical Trial With APD421 For Nausea & Vomiting
7th February 2011
Acacia Pharma Completes Phase I Clinical Trial With APD515 For Xerostomia
6th January 2011
Acacia Pharma Starts Clinical Trial With APD515 For Xerostomia
6th January 2011
Acacia Pharma Launches New Website
6th September 2010
Acacia Pharma to Progress Two Projects for Nausea & Vomiting and Xerostomia into Development
14th December 2009
Acacia Pharma Completes Phase II Study with APD405 in Post-Operative Nausea & Vomiting (PONV)
8th June 2009
Acacia Pharma Initiates Phase II Study with APD405 in Post-Operative Nausea & Vomiting (PONV)
31st March 2009
Acacia Pharma Initiates Phase IIa Study with APD209 in Cancer Cachexia Patients
5th February 2009
Acacia Pharma Appoints Ian Kent as Chairman
6th January 2009
Acacia Pharma Completes Clinical Trial with APD405 for Nausea & Vomiting
22nd September 2008
Acacia Pharma Starts First Clinical Trial with APD405 for Nausea & Vomiting
4th March 2008
Chief Medical Officer Appointed
4th March 2008
Gilde Healthcare Investment in Acacia Pharma
